Welcome to the Medical Services Advisory Committee
Technical Guidelines for Therapeutic ServicesPlease find below the draft Technical Guidelines for preparing assessment reports for the Medical Services Advisory Committee (MSAC) – Service Type: Therapeutic (Technical Guidelines for therapeutic services). This draft is released for the purpose of consultation.
This is the first release of draft Technical Guidelines for preparing assessment reports for MSAC with others to follow for Investigative Services and Consultation Services.
It is not intended that the document individually provides all the information applicants may need during the process of an MSAC assessment, only information relating to the development of a submission of evidence for assessment by the Evaluation Subcommittee (ESC) and MSAC for a therapeutic service. Some elements of the Technical Guidelines for therapeutic services are not yet complete. Additionally, some information is not intended to be included. For example:
- Information about drafting a decision analytic protocol (DAP) in the pre-assessment stage of the MSAC process is not included.
- Information about the timelines relating to the provision of a submission for consideration is not included and may be found on this website (see Committees – calendar, deadlines and agendas) or applicants may obtain this information from an application manager.
- Information about making an application that is based upon services that are co-dependent (must be provided together), and/or must be considered by more than one advisory committee (either the Pharmaceutical Benefits Advisory Committee or Prostheses Listing Advisory Committee) will be discussed in the Technical Guidelines for investigative services reflecting that most applications of this sort are for an investigative service that must be provided in association with a therapeutic service, device or medicine.
The final date for feedback from stakeholders is 23 November 2013. Following this, comments will be reviewed and changes drafted for consideration by MSAC.
During this consultation process, and while revisions are made, applicants may use these draft Technical Guidelines as a source of advice when developing submissions
MSAC Application FormThe Department is seeking to engage with stakeholders regarding the MSAC application form which has been amended to combine Parts A, B, C and D of the current application forms into one form to reduce repetition. The form has also been designed for users to complete electronically using Microsoft Word form fields with these fields expanding automatically when text is entered. As this document is under review, please contact the the HTA Team on (02) 6289 7550 for a copy of the current documentation.
More information on the MSAC application form can be found on the "How to list on the MBS" webpage.
Information Sessions held in March and April 2013For copies of the Information Session presentations held in Melbourne, Sydney and Brisbane on 21 and 22 March and 10 April respectively, please email the HTA Team.
After the 59th meeting of the Medical Services Advisory Committee's minutes for the following applications appraisal are available:
- Application 1147 – Implantation of fiducial markers into the prostate gland or prostate surgical bed for external beam radiotherapy
- Application 1152 – Genetic testing for hereditary mutations in the RET gene
- Application 1157 – Cell enrichment liquid-based cytology in routine screening for the prevention of cervical cancer
- Application 1161 - Gefitinib first line testing for mutations of epidermal growth factor receptor (EGFR) in patients with locally advanced or metastatic non-small cell lung cancer
- Application 1167– Addiction Medicine Consultation items
- Application 1171 – Sexual Health Consultation items
- Application 1168 – Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine
- Application 1173 - Testing for epidermal growth factor receptor (EGFR) status in patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC) for access to erlotinib
- Application 1207 - Diagnostic testing to determine the presence of V600 mutations in patients with locally advanced or metastatic melanoma
- Application 1293 - Epidermal growth factor receptor (EGFR) testing to determine eligibility for afatinib treatment in patients with locally advanced or metastatic non-small-cell lung cancer
- Application 1310 – Optical coherence tomography (OCT) for assessment of central retinal thickness in the presence of macular oedema secondary to central retinal vein occlusion for access to aflibercept
- Application 1330 – Transcatheter closure of a patent ductus arteriosus
- Application 1346 – Amendment to MBS item 11820
Completed Reviews, Assessments, Public Summary Documents and Assessment Reports
After the Medical Services Advisory Committee's consideration and noting of the advice by the Minister, the following completed reviews, assessments, public summary documents and assessment reports are available:
- 1299 – Proposed amendment to transperineal ultrasound prostate biopsy (MBS Item 37219)
- 1300 – Removal of gynaecomastia from the liposuction component in Barraquers-Simon’s syndrome (MBS Item 45585)
- 1180r – Review of Surgical treatment of obesity
- 1179r – Review of Colonoscopy Items
- 1178r – Review of Ophthalmology_Items (Stage-1)
- 1177r – Review of Pulmonary arterial catheters (PAC)
- 1176 – Assessment of application for Joint Injections
- 1156 – Diagnostic use of thyrotropin alfa-rch for patients with well-differentiated thyroid cancer
- 1153 – Genetic testing for hereditary mutation of the VHL gene
- 1144 – Pathology tests for mycobacterial infection
- 1146 – Capsule endoscopy for the diagnosis of suspected small bowel Crohn's disease
- 1139 – Measurement and determination of procalcitonin (PCT)
- 1054.1 – Review of interim funded service: hyperbaric oxygen therapy (HBOT) for the treatment of chronic non-diabetic wounds and non-neurological soft tissue radiation injuries
- Ref 38 – Gene amplification tests for determining HER-2 status in breast cancer
How to list on the MBS
Subscribe to MSAC Email Bulletin to be notified of:Meeting Agenda Items
Opportunities to Provide Feedback on Options for the Funding of Proposed Healthcare Interventions
Recently Released Assessments
A deadline for comment on both guideline documents will be set once the draft version of the full guidelines is released. Please forward any comments to the HTA Team.
Health Technology Assessment (HTA) WebsiteThe website is part of the Australian Government's response to the December 2009 Review of Health Technology Assessment in Australia (HTA Review) and arose from stakeholders identifying the need to have comprehensive information about Australian Government HTA processes available in one central point in an easy to use format.
The website also provides a portal to the HTA Access Point (referred to during the HTA Review as a single entry point) which will assist potential applicants seeking assessment of co-dependent and hybrid technologies.
Access the new Australian government HTA website.Back to Top
Page currency, Latest update: 28 October, 2013
When accessing large documents (over 500 KB in size), it is recommended that the following procedure be used:
- Click the link with the RIGHT mouse button
- Choose "Save Target As.../Save Link As..." depending on your browser
- Select an appropriate folder on a local drive to place the downloaded file
Attempting to open large documents within the browser window (by left-clicking)
may inhibit your ability to continue browsing while the document is
opening and/or lead to system problems.
To view PDF (Portable Document Format) documents, you will need to have a PDF reader installed on your computer. A number of PDF readers are available through the Australian Government Information Management Office (AGIMO) Web Guide website.